Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance

The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM... BackgroundGlioblastoma (GBM) is a difficult to treat brain cancer that nearly uniformly recurs, and recurrent tumors are largely therapy resistant. Our prior work has demonstrated an important role for the tumor necrosis factor–like weak inducer of apoptosis (TWEAK) receptor fibroblast growth factor–inducible 14 (Fn14) in GBM pathobiology. In this study, we investigated Fn14 expression in recurrent GBM and in the setting of temozolomide (TMZ) resistance.MethodsFn14 mRNA expression levels in nonneoplastic brain, primary (newly diagnosed) GBM, and recurrent GBM (post-chemotherapy and radiation) specimens were obtained from The Cancer Genome Atlas data portal. Immunohistochemistry was performed using nonneoplastic brain, patient-matched primary and recurrent GBM, and gliosarcoma (GSM) specimens to examine Fn14 protein levels. Western blot analysis was used to compare Fn14 expression in parental TMZ-sensitive or matched TMZ-resistant patient-derived xenografts (PDXs) established from primary or recurrent tumor samples. The migratory capacity of control and Fn14-depleted TMZ-resistant GBM cells was assessed using the transwell migration assay.ResultsWe found that Fn14 is more highly expressed in recurrent GBM tumors than their matched primary GBM counterparts. Fn14 expression is also significantly elevated in GSM tumors. GBM PDX cells with acquired TMZ resistance have higher Fn14 levels and greater migratory capacity than their corresponding parental TMZ-sensitive cells, and the migratory difference is due, at least in part, to Fn14 expression in the TMZ-resistant cells.ConclusionsThis study demonstrates that the Fn14 gene is highly expressed in recurrent GBM, GSM, and TMZ-resistant GBM PDX tumors. These findings suggest that Fn14 may be a valuable therapeutic target or drug delivery portal for treatment of recurrent GBM and GSM patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neuro-Oncology Oxford University Press

The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance

Download PDF
10 pages

Loading next page...
 
/lp/ou_press/the-tnf-receptor-family-member-fn14-is-highly-expressed-in-recurrent-4GBxdAT10n
Publisher
Oxford University Press
Copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
ISSN
1522-8517
eISSN
1523-5866
DOI
10.1093/neuonc/noy063
Publisher site
See Article on Publisher Site

Abstract

BackgroundGlioblastoma (GBM) is a difficult to treat brain cancer that nearly uniformly recurs, and recurrent tumors are largely therapy resistant. Our prior work has demonstrated an important role for the tumor necrosis factor–like weak inducer of apoptosis (TWEAK) receptor fibroblast growth factor–inducible 14 (Fn14) in GBM pathobiology. In this study, we investigated Fn14 expression in recurrent GBM and in the setting of temozolomide (TMZ) resistance.MethodsFn14 mRNA expression levels in nonneoplastic brain, primary (newly diagnosed) GBM, and recurrent GBM (post-chemotherapy and radiation) specimens were obtained from The Cancer Genome Atlas data portal. Immunohistochemistry was performed using nonneoplastic brain, patient-matched primary and recurrent GBM, and gliosarcoma (GSM) specimens to examine Fn14 protein levels. Western blot analysis was used to compare Fn14 expression in parental TMZ-sensitive or matched TMZ-resistant patient-derived xenografts (PDXs) established from primary or recurrent tumor samples. The migratory capacity of control and Fn14-depleted TMZ-resistant GBM cells was assessed using the transwell migration assay.ResultsWe found that Fn14 is more highly expressed in recurrent GBM tumors than their matched primary GBM counterparts. Fn14 expression is also significantly elevated in GSM tumors. GBM PDX cells with acquired TMZ resistance have higher Fn14 levels and greater migratory capacity than their corresponding parental TMZ-sensitive cells, and the migratory difference is due, at least in part, to Fn14 expression in the TMZ-resistant cells.ConclusionsThis study demonstrates that the Fn14 gene is highly expressed in recurrent GBM, GSM, and TMZ-resistant GBM PDX tumors. These findings suggest that Fn14 may be a valuable therapeutic target or drug delivery portal for treatment of recurrent GBM and GSM patients.

Journal

Neuro-Oncology – Oxford University Press

Published: Sep 3, 2018

References

  • Malignant gliomas in adults
    Wen
  • CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014
    Ostrom
  • Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    Stupp
  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
    Stupp
  • Targeting adaptive glioblastoma: an overview of proliferation and invasion
    Xie
  • Molecular targets of glioma invasion
    Nakada
  • Invasion as target for therapy of glioblastoma multiforme
    Vehlow
  • A neurocentric perspective on glioma invasion
    Cuddapah
  • A comprehensive profile of recurrent glioblastoma
    Campos
  • Standards of care for treatment of recurrent glioblastoma—are we there yet
    Weller
  • Molecularly targeted therapies for recurrent glioblastoma: current and future targets
    Lau
  • Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy
    Mangraviti
  • CCR 20th anniversary commentary: bevacizumab in the treatment of glioblastoma—the progress and the limitations
    Mar
  • Overcoming therapeutic resistance in glioblastoma: the way forward
    Osuka
  • Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy
    Auffinger
  • Genetic evolution of glioblastoma stem-like cells from primary to recurrent tumor
    Orzan
  • Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution
    Kim
  • Clonal evolution of glioblastoma under therapy
    Wang
  • Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma
    Byron
  • Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment
    van Thuijl
  • Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence
    Nickel
  • Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
    Johnson
  • The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting
    Winkles
  • TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities
    Burkly
  • TWEAK/Fn14 axis-targeted therapeutics: moving basic science discoveries to the clinic
    Cheng
  • The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors
    Tran
  • Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome
    Tran
  • The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics
    Perez
  • Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function
    Fortin
  • Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model
    Kitange
  • Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma
    Gupta